Oncolytics Biotech® Announces Positive Clinical Trial Results for Pelareorep in Patients with KRAS Mutant Metastatic Colorectal Cancer for Presentation at ESMO 2018
October 22, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
- Pelareorep more than doubles overall survival at recommended phase two dose as compared to historical phase 3 data - CALGARY, Alberta and SAN DIEGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Oncolytics...
Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress
October 11, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
- Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data - CALGARY, Alberta and SAN DIEGO, Oct. 11, 2018 (GLOBE NEWSWIRE)...
Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies
October 02, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic...
Oncolytics Biotech® Enters into Common Stock Purchase Agreement for up to US$26 Million with Lincoln Park Capital, LLC
September 28, 2018 08:36 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY), (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic...
Oncolytics Biotech® to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 26, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing pelareorep, an intravenously delivered immuno-oncolytic...
Oncolytics Biotech® Provides Corporate and Clinical Update
September 19, 2018 16:00 ET
|
Oncolytics Biotech, Inc.
- Webcast and conference call for investors and analystson Thursday, September 20 at 8:30 a.m. EDT - CALGARY, Alberta and SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc....
Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care
September 17, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX: ONC) (NASDAQ: ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep
September 10, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Announces a Master Clinical Supply Agreement of an Anti-PD-L1 Checkpoint Inhibitor for use in the Company’s Clinical Program
September 06, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered...
Oncolytics Biotech® Reports 2018 Second Quarter Results
August 03, 2018 07:00 ET
|
Oncolytics Biotech, Inc.
CALGARY, Alberta and SAN DIEGO, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing REOLYSIN® (pelareorep), an intravenously delivered...